PROMISE, an IMI project, will take the fight against the Respiratory Syncytial Virus (RSV) a step further

Teamit Research participates as a full partner in PROMISE (Preparing for RSV Immunisation and Surveillance in Europe), a new IMI (Innovative Medicines Initiative) project that just kicked off this November 1st.

Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms but can be potentially life-threatening for young children and older adults. There is still no medication or vaccine available to fight severe cases of RSV, a disease that costs governments around the world nearly 5 billion euros every year.

To help revert the current situation, the PROMISE project will focus on advancing knowledge on  (RSV) to better inform vaccination policies and drug development in Europe and worldwide. The project is led by the pharmaceutical company Sanofi-Pasteur and coordinated by the University of Edinburgh (UEDIN) and the University Medical Centre Utrecht (UMCU).  The PROMISE Consortium is formed by 22 partners from both the public and private sector and will receive 7 million euros funding from IMI until April 2024.

PROMISE will further research on RSV to support public health strategies and the development and monitoring of novel immunisation and therapeutics against this potentially deadly virus in the paediatric and elderly populations.

PROMISE builds on RESCEU (REspiratory Syncytial virus Consortium in Europe), an ongoing IMI project of which Teamit is also a partner. RESCEU has already made a significant contribution to the study of RSV. Its results have been widely disseminated in top tier journals. Now, PROMISE will take the fight against RSV one step further by generating new insights on RSV, identifying new diagnostic tools and prophylactic interventions, and developing a robust surveillance network on this disease. Moreover, the project will attempt to evaluate the impact of COVID-19 on RSV epidemiology with a special focus on older adults.

The project will also attempt to evaluate the impact of COVID-19 on RSV epidemiology with a special focus on older adults.

Besides being an active partner in RESCEU, Teamit has being involved in writing the proposal for PROMISE. It will now play an active role in the strategic direction and management of the project and in the design and implementation of the communication and dissemination plan.

See more projects managed by Teamit here.